Companies › Vogenx
1 active drug program in 2 registered trials: 2 Phase 2; Metabolic and endocrine; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Mizagliflozin 5 mg SGLT1 inhibitor | SLC5A1 | Phase 2 | Postbariatric Hypoglycemia | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07760961 | Mizagliflozin 5 mg | Phase 2 | Postbariatric Hypoglycemia | Metabolic and endocrine | Oct 2027 |
| NCT07760961 | Mizagliflozin 5 mg | Phase 2 | Postbariatric Hypoglycemia | Metabolic and endocrine | Oct 2027 |
Cash and short-term investments of $82m on 2026-09-30; operating cash outflow about $4m a year; runway about 252 months at that burn, to Sep 2047; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Lexicon Pharmaceuticals vTv Therapeutics SAb Biotherapeutics Amorphical ERX Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.